Technology
Health
Pharmaceutical

ArQule

$4.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-6.23%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ArQule and other stocks, options, ETFs, and crypto commission-free!

About

ArQule, Inc. Common Stock, also called ArQule, is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. Read More The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.

Employees
36
Headquarters
Burlington, Massachusetts
Founded
1993
Market Cap
525.40M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.48M
High Today
$5.13
Low Today
$4.80
Open Price
$5.11
Volume
816.16K
52 Week High
$7.21
52 Week Low
$2.23

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Research And Development
Therapy
US

News

Markets InsiderMar 15

ArQule Announces Management Team Changes

ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial Officer and Head of Strategy, effective as of Mr. Weiskopf’s retirement. Dr. Schegerin joined ArQule in May 2018 and most recently served as Senior Vice President, Head of Strategy, Finance and Communication. "Rob has played a ...

764
BusinessWireMar 13

ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10:20 a.m. ET at the Westin New York Grand Central in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule....

131
BusinessWireMar 11

ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California. About ArQule ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and...

729

Earnings

-$0.11
-$0.06
-$0.00
$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 6, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.